-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 DQYUV6FMWYnovYWT20C+wvaVDLEI6x6xC4oD7uFla/WzlMKYTTclZRodUvgESsrm
 gIhIgFNznazOkyUO+5Ajbw==

<SEC-DOCUMENT>0001102624-05-000165.txt : 20050720
<SEC-HEADER>0001102624-05-000165.hdr.sgml : 20050720
<ACCEPTANCE-DATETIME>20050720084630
ACCESSION NUMBER:		0001102624-05-000165
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20050720
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20050720
DATE AS OF CHANGE:		20050720

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		05962782

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>immucell8k.htm
<DESCRIPTION>IMMUCELL 8-K
<TEXT>
<table cellpadding="3" border="0" cellspacing="0" width="100%">
<tr><td>
</td></tr>
</table>
<center>
<table border=0 cellpadding=3 cellspacing=0>
<tr><td align="center"><br><br>
<B>UNITED STATES</B><br>
<B>SECURITIES AND EXCHANGE COMMISSION</B><br>
Washington, D.C. 20549<p>
<hr size=1>
<p><b>FORM 8-K<p>
CURRENT REPORT
<p>
Pursuant to Section 13 or 15(d) of the<br>Securities Exchange Act of 1934.
</td>
</tr>
</table>
<p>
<b>
<table border=0 cellpadding=0 cellspacing=0>
<tr><td colspan=5 align=center>
<b>Date of Report: July      20, 2005</b><br>
(Date of earliest event reported)<br><br>
</td></tr>
<tr><td colspan=5 align=center>
<b>ImmuCell Corporation</b><br>
(Exact name of registrant as specified in its charter)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align=center colspan=2 valign="top">
<b>DE</b><br>
(State or other jurisdiction <br>of incorporation)
</td>
<td align=center width="20%" valign="top">
<b>0-15507</b><br>
(Commission File Number)
</td>
<td align=center colspan=2 valign="top">
<b>01-0382980</b><br>
(IRS Employer <br>Identification Number)
</td>
</tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align="center" colspan=2>
<b>56 Evergreen Drive, Portland, ME</b><br>
(Address of principal executive offices)
</td>
<td>&nbsp;</td>
<td align="center" colspan=2>
<b>04103</b><br>
(Zip Code)
</td>
</tr>
<tr><td colspan=5 align=center><br>
<b>(207) 878-2770</b><br>(Registrant's telephone number, including area code)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr><td colspan=5 align=center>
<b>Not Applicable</b><br>(Former Name or Former Address, if changed since last report)<br>
</td></tr>
</table>
</center>
<br><br>
</b>
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<br>
<dl>
 <dd><font face="wingdings">o</font> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
 <dd><font face="wingdings">o</font> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  <br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  <br>
</dl>
<hr size=1>
<table width=100%>
<tr><td width="100%">
<b>Item 2.02. Results of Operations and Financial Condition</b></b><br>
<br>
On July 20, 2005 ImmuCell Corporation (the "Company") issued a press release announcing earnings results for the three and six month periods ended June 30, 2005. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
<br>
<br>The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 of the Exchange Act, except as expressly set forth by specific reference in such filing.
<br>
<br>
<p>
<b>Item 9.01. Financial Statements and Exhibits</b></b><br>
<br><b>(a) Financial statements:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(b) Pro forma financial information:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(c) Exhibits</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  99.1 &nbsp; &nbsp; &nbsp; <a href="immucellcorporation.htm">Press Release of ImmuCell Corporation dated July      20, 2005</a></b>
<p>
<p>
<hr size=1>
<b><center>SIGNATURE</center></b>
<p>
&nbsp; &nbsp; &nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
              signed on its behalf by the undersigned hereunto duly authorized.<p>
</td></tr>
</table>
<br>
<table>
<tr>
<td width="50%" valign=top>
Dated: July      20, 2005<br>
</td>
<td>
<b>IMMUCELL CORPORATION</b>
<p>
By: <u>&nbsp;/s/ Michael F. Brigham &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </u> <br>
&nbsp; &nbsp; &nbsp;Michael F. Brigham<br>
&nbsp; &nbsp; &nbsp;<i>President/CEO</i><br>
</td></tr>
</table>
<hr>
<center>
<table border=0 width="100%">
<tr><td colspan=2>
<center><b>Exhibit Index</b></center>
</td>
</tr>
<tr>
<td width=50% align=center><b><u>Exhibit No.</u></b></td>
<td width=50% align=center><b><u>Description</u></b></td>
</tr>
<tr>
<td align=center>99.1</td>
<td align=center>Press Release of ImmuCell Corporation dated July      20, 2005</td>
</tr>
</table>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>immucellcorporation.htm
<DESCRIPTION>IMMUCELL PRESS RELEASE
<TEXT>

<p></p>
<b>ImmuCell Announces Sales and Earnings Growth for Second Quarter and First Half of 2005</b>
<p>PORTLAND, ME -- 07/20/2005 --  ImmuCell Corporation (NASDAQ: ICCC) today
announced the results of its operations for the three and six month periods
ended June 30, 2005.
</p>
<p>
For the three months ended June 30, 2005, product sales increased by 32%,
or $206,000, to $848,000, in comparison to the same period in 2004.  For
the six months ended June 30, 2005, product sales increased by 22%, or
$417,000, to $2,276,000, in comparison to the same period in 2004.
</p>
<p>
"Our lead product, First Defense&#174;, continued to produce solid sales
gains," commented Michael F. Brigham, president and CEO.  "Most of our R&amp;D
efforts were invested in supporting the development of Mast Out&#174; under
our December 2004 licensing agreement with Pfizer."
</p>
<p>
The Company recognized net income of $79,000, or $0.03 per diluted share,
for the three months ended June 30, 2005, in contrast to a net loss of
$(58,000), or $(0.02) per share during the same period in 2004.  For the
six months ended June 30, 2005, the Company recognized net income of
$339,000, or $0.11 per diluted share, in comparison to net income of
$114,000, or $0.04 per diluted share during the same period in 2004.
</p>
<p>
The Company's cash, cash equivalents and short-term investments increased
by 11%, or $475,000, to $4,925,000 at June 30, 2005, as compared to
$4,450,000 at December 31, 2004.  Stockholders' equity increased by 6%, or
$454,000, to $8,183,000 at June 30, 2005, as compared to $7,729,000 at
December 31, 2004.  The Company had 2,847,000 shares of common stock
outstanding as of June 30, 2005.
<pre>

                                    (Unaudited)            (Unaudited)
                                 Three Months Ended     Six Months Ended
(In thousands, except per             June 30,               June 30,
 share amounts)                   2005       2004        2005       2004
Revenues:                       -------    -------     -------    -------
Product sales                   $   848    $   642     $ 2,276    $ 1,860
Other revenues                      136         23         304         47
                                -------    -------     -------    -------
Total revenues                      984        665       2,580      1,907

Cost and expenses:
Product costs                       349        300         911        759
Research and development
 expenses                           253        241         567        463
Selling, general and
 administrative expenses            278        234         585        516
                                -------    -------     -------    -------
Total costs and expenses            880        775       2,063      1,738
                                -------    -------     -------    -------
Net operating income (loss)         104       (110)        517        169

Interest and other income            31         15          52         26
                                -------    -------     -------    -------

Income (loss) before
 income taxes                       135        (95)        569        195
Income tax expense (benefit)         56        (37)        230         81
                                -------    -------     -------    -------
Net income (loss)               $    79    $   (58)    $   339    $   114
                                =======    =======     =======    =======

Net income (loss) per
 common share:
Basic                           $  0.03    $ (0.02)    $  0.12    $  0.04
Diluted                         $  0.03    $ (0.02)    $  0.11    $  0.04

Weighted average common
 shares outstanding:
Basic                             2,804      2,758       2,799      2,751
Diluted                           2,956      2,758       2,976      2,947


                                          (Unaudited)
                                          At June 30,     At December 31,
                                              2005             2004
(In thousands)                              -------          -------
Cash, cash equivalents and
 short-term investments                     $ 4,925          $ 4,450
Total assets                                  9,785            9,530
Net working capital                           5,533            4,998
Stockholders' equity                        $ 8,183          $ 7,729
</pre>
ImmuCell Corporation is a biotechnology company that is developing,
manufacturing and selling products that improve animal health and
productivity in the dairy and beef industries.  Press releases and other
information about the Company are available at http://www.immucell.com.

</p>
<pre>
Contact:
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106


</pre>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
